jstratt

jstratt
Send Message
View as an RSS Feed
  • FDA clears Merck's single-tablet HCV combo  [View news story]
    http://tinyurl.com/zba...
    Jan 28, 2016. 11:02 PM | Likes Like |Link to Comment
  • FDA clears Merck's single-tablet HCV combo  [View news story]
    This is the best of all worlds for GILD.

    It is competition but so inferior that it isnt really competition. BAML also states that it will have bigger problems when the Pan Genotype drug is approved in Jun.
    Jan 28, 2016. 10:34 PM | 1 Like Like |Link to Comment
  • Biogen Reports Q4: Analysis Of Operations And Its Pipeline  [View article]
    Enjoyed understanding your view on BIIB!

    I find anti Lingo interesting but really have more confidence in AMGN/CELG/GILD.

    The internal turmoil and poor performance early in 2015 along with lack of near term prospects still resonates even if the long journey down to $260s provides a sense of value.
    Jan 28, 2016. 02:42 PM | Likes Like |Link to Comment
  • 3 Must Own Biotech Stocks For February  [View article]
    Enjoyed the article!

    I continue to like AMGN, CELG and GILD.

    AMGN has escalating revenue growth leading into this quarter. It has close to 32% of revenue dropping to the bottom line vs 25% last year due to cost cutting. Further with 6 drugs introduced last year including Repatha and another half dozen enjoying double digit growth lot of room for optimism.

    CELG has a wonderful growth plan laid out and articulated for investors. Both history and an open book for the future suggests great promise at a reasonable price.

    GILD is so cheap at 7.5X PE it is a no brainer. If you subtract the cash it is about a 6 PE. When GILD launches into curing the world with its Pan genotype drug in 2016 the impact of 180MM patients will start to be appreciated.

    I am less interested in those companies relying on price increases rather than innovation.
    Jan 27, 2016. 01:54 PM | 3 Likes Like |Link to Comment
  • Apple And Chill  [View article]
    a couple of thoughts on AAPL...

    - in a scared market AAPL is short term undervalued. Especially if you subtract cash and calculate a P/CF analysis

    - LT investors have reason for concern. That has been true for the past 5 years as well however.

    - Cramer/CNBC and others are heavily pumping AAPL. If I wait I think I can buy shares around $90 when the market bottoms.
    Jan 27, 2016. 12:15 PM | 1 Like Like |Link to Comment
  • Biogen beats by $0.42, beats on revenue  [View news story]
    I just dont trust BIIB. That meant selling shares at $303 to invest in AMGN/CELG/GILD.

    If you are patient you can probably buy BIIB shares back below $270 but my view was that the Alzheimers news earlier this year was at least 50% marketing to cover up poor performance.
    Jan 27, 2016. 11:20 AM | Likes Like |Link to Comment
  • International Business Machines declares $1.30 dividend  [View news story]
    The stock rises 15% when they fire Rometty and develop a coherent strategy.

    With 15 straight down quarters and 4 more projected by company guidance it is hard to imagine why you would invest. IBM was around $200 4 years ago when she was elected Chmn and now it is $122.

    I do predict that IBM will beat its -29% guidance for 1Q 2016. The headline will read "IBM Beats" as it will only be down -27%. SA commenters will proclaim the quarter a success and marvel at the 4.5% dividend.
    Jan 26, 2016. 04:47 PM | 3 Likes Like |Link to Comment
  • IBM's 4%+ Yield: Bad News... Good News... I Can Wait  [View article]
    IBM is also worth more than dog poop!

    IBM's leadership proving they are experts in the cloud decided to buy the Weather Channel.
    Jan 26, 2016. 03:03 PM | 2 Likes Like |Link to Comment
  • Johnson & Johnson: Like Clockwork  [View article]
    Were I to have to make an additional investment today JNJ would be a strong candidate.

    I hold a fair amount of JNJ and if the author owned shares in the past year he might not have felt everything was like Clockwork.

    A 15.7 PE along with an attractive dividend yield is quite reasonable.
    Jan 26, 2016. 01:03 PM | 3 Likes Like |Link to Comment
  • Freeport-McMoRan: On Life Support  [View article]
    I liked what I heard today.

    Production at $1.45 copper and $16 Oil should ensure survival. That doesnt mean it will look like it at every moment into the long term however.
    Jan 26, 2016. 12:40 PM | 4 Likes Like |Link to Comment
  • 4 Takeaways From Freeport-McMoRan Q4 Report  [View article]
    Lots of good in this report.

    thoughts

    - FCX will survive with $1.45 oz cost to produce Copper and $16 to produce Oil.

    - Cash flow positive given reasonable assumptions

    - write downs must be nearly over and valuation at 17.38% of EV

    - Vlad is correct no need to rush in but the set up ahead of Oil capitulation is attractive.
    Jan 26, 2016. 12:27 PM | 3 Likes Like |Link to Comment
  • Why Dip Buyers Will Get Clobbered: The U.S. Economy Isn't Doing 'Just Fine'  [View article]
    The only problem with this article is the premise isnt true.

    As an example in early 2007 discussion of a financial crisis started and it continued with numbers increasing from millions to billions to hundreds of billions...

    By the start of 2008 everyone was well aware that a financial problem existed and a recession was a strong possibility. By Jun 2008 a full financial drop off was under way.

    One should never lose sight of financial issues and the impact on markets. Still blatent misrepresentation doesnt add value.
    Jan 26, 2016. 10:29 AM | 19 Likes Like |Link to Comment
  • Valeant's Pearson still uncertain on return to work  [View news story]
    After the Senate hearings are over he will stage a miraculous recovery.
    Jan 26, 2016. 09:25 AM | 1 Like Like |Link to Comment
  • Biotech Deserves A Piece Of Every Dividend Growth Portfolio  [View article]
    I enjoyed an interesting view of both GILD and AMGN prospects.

    Most investors would do well to think of them as large pharma companies with huge cash flows, growing dividend returns and growing businesses.

    Since the average S&P500 company has declining earnings I find much less risk in these names than in most other S&P categories. My investment mix includes CELG as well.

    An investment in AMGN, GILD and CELG at current levels I believe has lower risk and much higher return probabilities than the market itself. Growth is hard to find and at a reasonable price is unusual.
    Jan 25, 2016. 11:36 PM | 4 Likes Like |Link to Comment
  • Gilead Closes Galapagos Deal- Opens Up Massive Market Opportunity  [View article]
    I wasnt impressed by the Galapagos deal.

    That said GILD certainly intends to combine it with other pipeline drugs and sees a market or markets to attack. Given company history it will likely be at least marginally profitable.

    My hope remains that GILD is able to advance HBV research by the end of 2016. With the 5 drugs in works and huge effort underway I think that is very possible.
    Jan 25, 2016. 09:20 AM | 2 Likes Like |Link to Comment
COMMENTS STATS
3,578 Comments
6,102 Likes